Sunday 18 October 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 8.33% and free cash flow fell 3.16%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.06
0.10
−4.63%
Follow NAUT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(32.00%) | (32.27%) | (33.69%) | (36.21%) | |
| (27.27%) | (27.20%) | (28.16%) | (30.00%) | ||
ROIC |
(118.33%) | (77.97%) | (82.53%) | (83.32%) | |
Return on Tangible Assets |
(48.71%) | (58.15%) | (60.65%) | (68.11%) | |
Free Cash Flow per Share |
(0.43) | (0.41) | (0.41) | (0.41) | |
Free Cash Flow |
(53.92) | (51.97) | (51.43) | (51.86) | |
Capital Expenditures |
(1.29) | (1.28) | (1.57) | (1.63) | |
| Other line items | |||||
Cash ROIC |
(17.94%) | (19.96%) | (21.40%) | (24.11%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 2.87 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 134.80 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.86 | 0.87 | 0.89 | |
Depreciation/Fixed assets |
1.27 | 1.46 | 1.48 | 1.37 | |
Capex/Depreciation |
(0.28) | (0.25) | (0.29) | (0.30) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.42) | (0.40) | (0.39) | (0.40) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates